{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["41(1)"],"submitter":["Amin HM"],"pubmed_abstract":["<h4>Background and objective</h4>Targeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.<h4>Methods</h4>A systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.<h4>Results</h4>Seven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and "],"journal":["International journal of colorectal disease"],"pagination":["1"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12764650"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials."],"pmcid":["PMC12764650"],"pubmed_authors":["Hasan A","Gardezi SA","Albustanji Q","Ahmed R","Shahzad M","Ahmed M","Abukhater R","Hasan S","Khalid SM","Majeed S","Lilley R","Atique A","Shahzad MA","Amin HM","Sadique H","Shoaib MS"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.","description":"<h4>Background and objective</h4>Targeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.<h4>Methods</h4>A systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.<h4>Results</h4>Seven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T10:20:49.783Z","creation":"2026-05-28T03:13:06.494Z"},"accession":"S-EPMC12764650","cross_references":{"pubmed":["41467943"],"doi":["10.1007/s00384-025-05014-5"]}}